Home » Archive

NYSE:PFE

Marketwire, News, NYSE:PFE, Syndication »

Lpath Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab

Posted by Mary Canady April 25th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 25, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that it has been issued a key patent prote…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab

Posted by Mary Canady April 25th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Apr 25, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that it has been issued a key patent prote…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Prepares to Continue iSONEP Trials in August

Posted by Mary Canady March 12th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 12, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, plans to manufacture new antibody drug substance in preparation for the continuation of its PEDigree and Nexus tri…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Raises $9.3 Million in Equity Financing

Posted by Mary Canady March 6th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 6, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has entered into subscription agreements with various investors to raise approximately $9.3 million through the sal…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source

Posted by Mary Canady January 26th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 26, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has temporarily suspended dosing patients in its PEDigree and Nexus trials. In these trials, iSONEPT is being test…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source

Posted by Mary Canady January 26th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 26, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has temporarily suspended dosing patients in its PEDigree and Nexus trials. In these trials, iSONEPT is being test…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Schedules Investor Update Conference Call for Thursday, October 27, 2011 at 4:30 p.m. ET

Posted by Mary Canady October 21st, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Oct 21, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, will hold a conference call on Thursday, October 27, 2011 at 4:30 p.m. Eastern time to provide a status update and…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Initiates Dosing of iSONEP in Second of Two Proof-of-Concept Trials

Posted by Mary Canady October 17th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Oct 17, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has initiated dosing in its Nexus clinical trial, in which iSONEPT is being investigated as a treatment for wet AM…

More...

NYSE:PFE »

Lpath Granted Two Additional U.S. Patents Related to iSONEP and ASONEP Drug Programs

Posted by Mary Canady October 5th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Oct 5, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that Lpath has been issued two fur…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Granted Two Additional U.S. Patents Related to iSONEP and ASONEP Drug Programs

Posted by Mary Canady October 5th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Oct 5, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that Lpath has been issued two fur…

More...